Guidelines: ESH
Guidelines: ISH
Home > June 2018 - Volume 36 - Issue > RELATIONSHIPS BETWEEN SERUM URIC ACID AND BLOOD PRESSURE, ME...
< Previous Abstract
Next Abstract >
Colleague's E-mail is Invalid
Thought you might appreciate this item(s) I saw at Journal of Hypertension.
Your message has been successfully sent to your colleague.
Email To Colleague
Alert Me When Cited
RELATIONSHIPS BETWEEN SERUM URIC ACID AND BLOOD PRESSURE, METABOLIC VARIABLES AND CARDIOVASCULAR RISK PROFILE IN TREATED HYPERTENSIVE PATIENTS FROM CENTRAL AND EASTERN EUROPEAN COUNTRIES: RESULTS OF THE BP-CARE STUDY
Redon, P.1,2; Facchetti, R.3; Maloberti, A.3; Bombelli, M.3; Redon, J.2,4; Lurbe, E.1,4; Mancia, G.3,5; Grassi, G.3,5
Journal of Hypertension: June 2018 - Volume 36 - Issue - p e2
doi: 10.1097/01.hjh.0000538968.58643.12
ORAL SESSION 1A: CARDIOVASCULAR RISK FACTORS: PDF Only
Author InformationAuthors
Objective: Limited information is available on the association between serum uric acid (SUA) and metabolic syndrome, diabetes mellitus, renal failure, blood pressure (BP) control and cardiovascular (CV) risk profile in treated hypertensives of eastern European countries.
Design and method: The BP-CARE study examined BP control and CV risk profile in about 8000 treated hypertensive patients followed by non-specialist or specialist physicians in Albania, Belarus, Bosnia, Czech Republic, Latvia, Romania, Serbia, Slovakia and Ukraine. In 3220 of them measurements included, along with clinic BP, 24-hour BP, metabolic and renal function variables, SUA values.
Results: 51% were males, while mean age (±SD) was 60.0 ± 10.9 yrs, clinic BP 147.3 ± 18/87.8 ± 10 mmHg, 24 hour BP 137.3 ± 19/81.3 ± 10 mmHg and SUA values 5.68 ± 1.9 mg/dl, with a normal distribution in the population. SUA was significantly higher in males than females (5.99 ± 1.9 vs 5.34 ± 1.9 mg/dl, P < 0.0001) and progressively and significantly greater from the low to the medium, high and very high risk patients (4.87 ± 1.38 vs 5.85 ± 2.00, P < 0.0001, ESH CV risk categories). Significant differences were also found between diabetic and non-diabetic patients (5.92 ± 2.2 vs 5.58 ± 1.8, P < 0.0001), patients with and without metabolic syndrome (5.92 ± 2.1 vs 5.43 ± 1.7, P < 0.0001) and from stage 1 to stage 5 renal insufficiency (from 5.87 ± 2.0 to 10.48 ± 3.4, P < 0.0001). No significant difference in SUA was found between patients treated and non-treated with diuretic or angiotensin II blockers or in those under antihypertensive drug combination vs monotherapy. No difference in SUA was also found when analyzing the data in relation to clinic or 24-hour BP control.
Conclusions: These data provide evidence that similarly to what described in western Europe, in central and eastern European countries SUA values are closely related to metabolic alterations, including diabetes mellitus, to renal insufficiency and CV risk profile. At variance from other studies, however, no relationship was found with BP control.
1Pediatric Department of Consorcio Hospital General Universitario de Valencia, Valencia, Spain
2CIBER Fisiopatología Obesidad y Nutrición, Instituto de Salud Carlos III, Valencia, Spain
3Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy
4Hypertension Clinic, Hospital Clinico, INCLIVA, University of Valencia, Valencia, Spain
5IRCCS Multimedica, Sesto San Giovanni, Milan, Italy
RELATIONSHIPS BETWEEN SERUM URIC ACID AND BLOOD PRESSURE, METABOLIC VARIABLES AND CARDIOVASCULAR RISK PROFILE IN TREATED HYPERTENSIVE PATIENTS FROM CENTRAL AND EASTERN EUROPEAN COUNTRIES:...
Journal of Hypertension36:e2, June 2018.
Articles in PubMed by P. Redon
Articles in Google Scholar by P. Redon
Other articles in this journal by P. Redon
Readers Of this Article Also Read
2003 World Health Organization (WHO)/International Society of Hypertension (ISH) statement on management of hypertension
Antihypertensive classes, cognitive decline and incidence of dementia: a network meta-analysis
2013 ESH/ESC Guidelines for the management of arterial hypertension: The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)
Factors involved in the discontinuation of antihypertensive drug therapy: an analysis from real life data
Effects of blood pressure lowering on outcome incidence in hypertension. 1. Overview, meta-analyses, and meta-regression analyses of randomized trials